“We are pleased with the progress we have made in the first quarter and we are confident in the continued growth of CAPLYTA,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “We are excited about our recent positive results in our clini...
Intra-Cellular TherapiesITCIsigned a definitive agreement with pharma bigwigJohnson & JohnsonJNJ. Per the terms, the pharma giant will acquire all outstanding shares of ITCI for $132 per share in cash, aggregating to nearly $14.6 billion. A commercial-stage biotech company, Intra-Cellular is focu...
“CAPLYTA®’s success and the robust pipeline we have built demonstrates the passion and dedication of our talented team, and we are proud of the hundreds of thousands of patients we have helped,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular ...
Pipeline & Products From bench to bedside, a diverse portfolio of investigational compounds across different stages of drug development. Read More CAPLYTA is a registered trademark of Intra-Cellular Therapies, Inc. US-CAP-2500150 3/25© 2025 Johnson & Johnson and its affiliates. All rights ...
The acquisition also includes a clinical-stage pipeline that further complements and strengthens Johnson & Johnson's current areas of focus. "We are excited to welcome the talented people and world-class expertise of Intra-Cellular Therapies to Johnson & Johnson," said Jennifer Taubert, Executive ...
强生将以132美元/股现金收购Intra-Cellular Intra-Cellular Therapies(ITCI)131.870.00% 强生(JNJ)149.30-3.14% Informatica Inc.(NYSE)0.000.00% Johnson & Johnson (NYSE:JNJ) hasagreed to acquireall outstanding shares of biopharmaceutical company Intra-Cellular Therapies (NASDAQ:ITCI) for $132.00 a share ...
Intra-Cellular Therapies, Inc. today announced that it will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 at 1:30 p.m. ET.
The SIMPLI pipeline (Bortolomeazzi et al., 2022) was used for image processing, analysis, and clustering. Data and statistical analysis were performed in R using T test corrected for multiple testing. Result Individual neuronal populations are not significantly reduced in AD samples...
We processed these raw datasets following a pipeline similar to BLUEPRINT (Chen et al., 2016) on these additional samples, detailed below. We aligned reads to hg38 (GRCh38) using BWA quality threshold of 15 (bwa aln -q 15). Duplicate reads and reads with mapping quality < 15 were ...
A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics 43, 11.10.1–11.10.33 (2013). Google Scholar McKenna, A. et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation ...